Esperion Therapeutics Inc (NASDAQ:ESPR) to Post Q4 2020 Earnings of $2.54 Per Share, Jefferies Financial Group Forecasts

Esperion Therapeutics Inc (NASDAQ:ESPR) – Equities researchers at Jefferies Financial Group cut their Q4 2020 earnings estimates for Esperion Therapeutics in a report released on Wednesday, November 6th. Jefferies Financial Group analyst M. Yee now expects that the biopharmaceutical company will post earnings per share of $2.54 for the quarter, down from their previous forecast of $2.67.

Several other equities analysts also recently commented on the stock. ValuEngine upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Goldman Sachs Group upgraded shares of Esperion Therapeutics from a “sell” rating to a “neutral” rating and lowered their target price for the stock from $55.00 to $45.00 in a research note on Monday, September 16th. BidaskClub upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th. Stifel Nicolaus lowered their target price on shares of Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, September 17th. Finally, Northland Securities reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, August 29th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $70.44.

NASDAQ:ESPR opened at $37.82 on Friday. The company has a fifty day simple moving average of $38.49 and a two-hundred day simple moving average of $42.58. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -5.02 and a beta of 1.86. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.01. Esperion Therapeutics has a 52 week low of $33.13 and a 52 week high of $58.90.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($2.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.95) by ($0.42). The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $0.99 million. During the same period last year, the business posted ($1.86) EPS.

In related news, major shareholder Target N. V. Biotech purchased 75,000 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The stock was purchased at an average cost of $37.30 per share, with a total value of $2,797,500.00. Following the completion of the transaction, the insider now directly owns 3,727,964 shares in the company, valued at $139,053,057.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Target N. V. Biotech purchased 80,000 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average cost of $33.78 per share, with a total value of $2,702,400.00. Following the completion of the transaction, the insider now owns 3,652,964 shares of the company’s stock, valued at $123,397,123.92. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 167,500 shares of company stock valued at $5,943,925. 7.70% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Aperio Group LLC purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at about $29,000. Russell Investments Group Ltd. purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at about $32,000. Royal Bank of Canada raised its holdings in shares of Esperion Therapeutics by 38.1% in the second quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 811 shares during the last quarter. Swiss National Bank raised its holdings in shares of Esperion Therapeutics by 2.0% in the second quarter. Swiss National Bank now owns 44,900 shares of the biopharmaceutical company’s stock valued at $2,089,000 after buying an additional 900 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Esperion Therapeutics by 1.1% in the second quarter. Bank of New York Mellon Corp now owns 104,247 shares of the biopharmaceutical company’s stock valued at $4,850,000 after buying an additional 1,114 shares during the last quarter.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Article: What is a growth and income fund?

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.